Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-CN54
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-CN54 is an experimental HIV vaccine candidate based on the Modified Vaccinia Ankara (MVA) viral vector platform. It expresses HIV-1 subtype C (CN54)-derived antigens, specifically the envelope glycoprotein gp120 (Env), as well as Gag, Pol, and Nef polyproteins. The vaccine is designed to induce both cellular and humoral immune responses against HIV-1 by presenting these antigens to the immune system. MVA-CN54 has been evaluated in phase 1 clinical trials as part of prime-boost regimens for prophylactic vaccination against HIV infection[1][3]. The primary developer is Imperial College London[2][3].
- Other names
- Modified Vaccinia Ankara-CMVA-C (97CN54)MVA-C (nominal titre)
02
Targets
Gag (HIV-1 Gag polyprotein)gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)Nef (HIV-1 Nef)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on MVA-CN54.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-CN54.